Joshi, Sunil K. http://orcid.org/0000-0003-2798-5762
Keck, Jamie M.
Eide, Christopher A.
Bottomly, Daniel
Traer, Elie
Tyner, Jeffrey W.
McWeeney, Shannon K. http://orcid.org/0000-0001-8333-6607
Tognon, Cristina E.
Druker, Brian J. http://orcid.org/0000-0001-8331-8206
Funding for this research was provided by:
Leukemia and Lymphoma Society (LLS SCOR 7005-11)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U54CA224019, 1R01CA214428)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Article History
Received: 18 February 2020
Revised: 10 April 2020
Accepted: 20 April 2020
First Online: 4 May 2020
Compliance with ethical standards
:
: BJD’s potential competing interests—SAB: Aileron Therapeutics, ALLCRON, Cepheid, Vivid Biosciences, Celgene, RUNX1 Research Program, EnLiven Therapeutics, Gilead Sciences (inactive), Baxalta (inactive), and Monojul (inactive); SAB and Stock: Aptose Biosciences, Blueprint Medicines, Beta Cat, Third Coast Therapeutics, GRAIL (inactive), and CTI BioPharma (inactive); Scientific Founder: MolecularMD (inactive, acquired by ICON); Board of Directors and Stock: Amgen; Board of Directors: Burroughs Wellcome Fund and CureOne; Joint Steering Committee: Beat AML LLS; Founder: VP Therapeutics; Clinical Trial Funding: Novartis, Bristol-Myers Squibb, and Pfizer; Royalties from Patent 6958335 (Novartis exclusive license) and OHSU and Dana-Farber Cancer Institute (one Merck exclusive license). SKJ, JMK, CAE, DB, and SKM declare no potential competing interests. CET’s potential competing interests—research funding from Ignyta (inactive). ET’s potential competing interests—Advisory Board: Agios, Astellas, Daiichi-Sankyo, and ImmunoGen; Clinical Trial Funding: Janssen, Incyte, and LLS Beat AML. JWT’s potential competing interests—research support from Agios, Aptose, Array, AstraZeneca, Constellation, Genentech, Gilead, Incyte, Janssen, Petra, Seattle Genetics, Syros, and Takeda.